{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:03:21Z","timestamp":1790035401764,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115379","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T18:58:35Z","timestamp":1742756315000},"page":"115379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Immunotherapy followed by cetuximab in locally advanced\/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-0224","authenticated-orcid":false,"given":"Paolo","family":"Bossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-1986","authenticated-orcid":false,"given":"Andrea","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7616-5125","authenticated-orcid":false,"given":"Cristiana","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-9759","authenticated-orcid":false,"given":"Carlo","family":"Resteghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":false,"given":"Laura Deborah","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-2275","authenticated-orcid":false,"given":"Salvatore","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-6859","authenticated-orcid":false,"given":"Stefano","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-844X","authenticated-orcid":false,"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-2635","authenticated-orcid":false,"given":"Cristina","family":"Gurizzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7557-1017","authenticated-orcid":false,"given":"Luigi","family":"Lorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-6298","authenticated-orcid":false,"given":"Manuel","family":"Zamparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-6266","authenticated-orcid":false,"given":"Vittorio","family":"Rampinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Grammatica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Patuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Maurichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-4118","authenticated-orcid":false,"given":"Lisa Francesca","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115379_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2025.115379_bib2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/DSS.0000000000000478","article-title":"Consensus for Nonmelanoma Skin Cancer Treatment, Part II: Squamous Cell Carcinoma, Including a Cost Analysis of Treatment Methods","volume":"41","author":"Kauvar","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2025.115379_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib4","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y","article-title":"Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin","volume":"66","author":"Sadek","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115379_bib5","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1002\/cam4.3146","article-title":"Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy","volume":"9","author":"Cowey","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.115379_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e18703","article-title":"Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and\/or radiation therapy","volume":"36","author":"Ruiz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.04.004","article-title":"Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer","volume":"97","author":"Cavalieri","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115379_bib9","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial","volume":"124","author":"Gold","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115379_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2017.07.048","article-title":"Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial","volume":"77","author":"William","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2025.115379_bib11","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib13","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib15","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1200\/JCO.2019.37.15_suppl.6015","article-title":"Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC)","volume":"37","author":"Migden","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115379_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115379_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2015.05.030","article-title":"EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-\u03baB","volume":"463","author":"Lin","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2025.115379_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115379_bib20","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115379_bib21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1349-7006.2007.00510.x","article-title":"Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor","volume":"98","author":"Kimura","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2025.115379_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/2326-6066.CIR-14-0188","article-title":"Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab","volume":"3","author":"Taylor","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2025.115379_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12026-011-8231-0","article-title":"Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity","volume":"50","author":"Lee","year":"2011","journal-title":"Immunol Res"},{"key":"10.1016\/j.ejca.2025.115379_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/mt.2012.184","article-title":"Cetuximab-mediated tumor regression depends on innate and adaptive immune responses","volume":"21","author":"Yang","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2025.115379_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737311","article-title":"The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2025.115379_bib26","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115379_bib27","doi-asserted-by":"crossref","first-page":"S654","DOI":"10.1016\/j.annonc.2023.09.2221","article-title":"1087MO A single-arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study","volume":"34","author":"Becker","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102172","article-title":"Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer","volume":"97","author":"Bourhis","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115379_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12957-023-03077-8","article-title":"Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study","volume":"21","author":"Zheng","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44276-024-00058-6","article-title":"Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors","volume":"2","author":"Conroy","year":"2024","journal-title":"BJC Rep"},{"key":"10.1016\/j.ejca.2025.115379_bib32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.21037\/atm-22-2669","article-title":"Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2025.115379_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000500246","article-title":"PD-L1 expression in unresectable locally advanced or metastatic skin squamous cell carcinoma treated with anti-epidermal growth factor receptor agents","volume":"97","author":"Cavalieri","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2025.115379_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e18027","article-title":"Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent\/metastatic head and neck squamous cell carcinomas (R\/M HNSCC) compared to larger delay","volume":"42","author":"Carulla","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2019.104523","article-title":"Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"101","author":"Pestana","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2025.115379_bib36","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1200\/JCO.2022.40.16_suppl.9519","article-title":"Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)","volume":"40","author":"Gross","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:47:24Z","timestamp":1760640444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"alternative-id":["S0959804925001601"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115379","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy followed by cetuximab in locally advanced\/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115379"}}